SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mkilloran who wrote (11853)7/21/1998 6:23:00 PM
From: VLAD  Read Replies (2) of 23519
 
martin,

CNBC is now having a report on the drug sector. Some interesting points to note:

S&P 500 PE based on 1999 forward earnings estimates is 21

Now for some drug companies and their PEs based on forward 1999 projected earnings:

Lilly 31

Bristol Meyers 31

Schering Plough 38

Warner Lambert 44

Also mentioned that many of these companies are looking for mergers and aquisitions and specifically pointed out J&J and its recent aquisitions. I really don't care what the shorts say. IMO Vivus if sold today at $20.00/share is a good deal for whatever company aquires them. It is especially a good deal if it is based on a stock swap. Come on Mr. Wilson, quit holding out for $30 to $40.00/share and sell NOW before you ruin what is left of our company!!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News